What exactly is this huge market they have a foothold in? The Russian pharmaceutical market is about 1.5% of the world market. Then you have to whittle down by indication and all of a sudden you are at an absolute maximum market of about $50 million year. Then you need to take account of competition, which might leave you with potential sales of $10 million. Next you then consider that they haven't released any data to demonstrate that Ropren does anything other than perhaps provide a bit of nutrients and, well, sales of $100,000 pa is probably around the mark.
If sla was serious, they would be going after the USA market (about 50% of the world market), performing proper clinical trials, releasing data to demonstrate their products work (like every other respectable company) and avoid making erroneous claims about demand for a product that isn't even on sale yet.
Bill
Add to My Watchlist
What is My Watchlist?
